Ito Kengo, Kato Takashi
Department of Brain Science and Molecular Imaging, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Obu, Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi. 2009 Aug;29(4):153-60.
Although there are already many reports about the usefulness of positron emission tomography with FDG (FDG-PET) in diagnosis of Alzheimer disease (AD) and scientific evidence has been established, further improvement in diagnostic ability is achieved by using statistical image analysis, such as SPM and 3D-SSP. FDG-PET is also expected to be able to predict conversion to AD in patients with mild cognitive impairment (MCI), and establishment of the scientific evidence by prospective clinical trial is indispensable. Although clinical application of amyloid imaging may enable super-early and pre-clinical diagnoses of AD, many unsolved problems still remain. PET can play an important role in clinical trials for developing new therapeutic drugs for AD.
尽管已有许多关于氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）在阿尔茨海默病（AD）诊断中的应用报告，且科学依据已经确立，但通过使用统计图像分析，如统计参数映射（SPM）和三维标准化摄取值比（3D-SSP），诊断能力可进一步提高。FDG-PET也有望能够预测轻度认知障碍（MCI）患者向AD的转化，而通过前瞻性临床试验确立科学依据是必不可少的。尽管淀粉样蛋白成像的临床应用可能实现AD的超早期和临床前诊断，但仍存在许多未解决的问题。PET在AD新型治疗药物研发的临床试验中可发挥重要作用。
